Drug Profile
Research programme: obesity therapy - Ambrx
Alternative Names: ARX-328Latest Information Update: 13 Mar 2024
Price :
$50
*
At a glance
- Originator Ambrx
- Class Adipokines
- Mechanism of Action Leptin receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Obesity
Most Recent Events
- 07 Mar 2024 Ambrx has been acquired by Johnson & Johnson
- 04 Nov 2017 No recent reports of development identified for preclinical development in Obesity in USA
- 09 Jan 2014 Preclinical development is ongoing in USA